Cefditoren PivoxilCephalosporin antibiotic CAS# 117467-28-4 |
- Alvimopan monohydrate
Catalog No.:BCC1349
CAS No.:1383577-62-5
- Alvimopan
Catalog No.:BCC1347
CAS No.:156053-89-3
- Alvimopan dihydrate
Catalog No.:BCC1348
CAS No.:170098-38-1
- JDTic
Catalog No.:BCC1670
CAS No.:361444-66-8
- ADL5859 HCl
Catalog No.:BCC1265
CAS No.:850173-95-4
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 117467-28-4 | SDF | Download SDF |
| PubChem ID | 6437877 | Appearance | Powder |
| Formula | C25H28N6O7S3 | M.Wt | 620.72 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Cefditoren pivoxyl; Cefditoren pivaloyloxymethyl ester; ME 1207 | ||
| Solubility | DMSO : ≥ 100 mg/mL (161.10 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 2,2-dimethylpropanoyloxymethyl (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate | ||
| SMILES | CC1=C(SC=N1)C=CC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)OCOC(=O)C(C)(C)C | ||
| Standard InChIKey | AFZFFLVORLEPPO-UVYJNCLZSA-N | ||
| Standard InChI | InChI=1S/C25H28N6O7S3/c1-12-15(41-10-27-12)7-6-13-8-39-21-17(29-19(32)16(30-36-5)14-9-40-24(26)28-14)20(33)31(21)18(13)22(34)37-11-38-23(35)25(2,3)4/h6-7,9-10,17,21H,8,11H2,1-5H3,(H2,26,28)(H,29,32)/b7-6-,30-16-/t17-,21-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Cefditoren pivoxil is a new-third generation cephalosporin antibiotic that has a broad spectrum of activity against Gram-positive and Gram-negative bacteria, including common respiratory and skin pathogens.
Target: Antibacterial
Cefditoren pivoxil, a new-third generation cephalosporin antibiotic that has recently been granted approval in Spain, shows important activity over a large part of the pathogens causing skin, soft tissue and respiratory tract infections, including Gram-negative and Gram-positive bacteria. Cefditoren is also marketed under the name Meiact. Cefditoren has a broad spectrum of activity and has been used to treat bacterial infections of the skin and respiratory tract including bronchitis, pneumonia, and tonsillitis. The following represents MIC susceptibility data for a few medically significant microorganisms.
Cefditoren has shown excellent in vitro activity against the Gram-positive pathogens penicillin-susceptible and -intermediate Streptococcus pneumoniae, S. pyogenes and methicillin-susceptible Staphylococcus aureus. Cefditoren was inactive against methicillin-resistant S. aureus. Of the important Gram-negative pathogens, cefditoren had potent antibacterial effects against beta-lactamase-positive and -negative Haemophilus influenzae, H. parainfluenzae and beta-lactamase-positive and -negative Moraxella catarrhalis. References: | |||||
Cefditoren Pivoxil Dilution Calculator
Cefditoren Pivoxil Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.611 mL | 8.0552 mL | 16.1103 mL | 32.2206 mL | 40.2758 mL |
| 5 mM | 0.3222 mL | 1.611 mL | 3.2221 mL | 6.4441 mL | 8.0552 mL |
| 10 mM | 0.1611 mL | 0.8055 mL | 1.611 mL | 3.2221 mL | 4.0276 mL |
| 50 mM | 0.0322 mL | 0.1611 mL | 0.3222 mL | 0.6444 mL | 0.8055 mL |
| 100 mM | 0.0161 mL | 0.0806 mL | 0.1611 mL | 0.3222 mL | 0.4028 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Cefditoren pivoxil is a new-third generation cephalosporin antibiotic that has a broad spectrum of activity against Gram-positive and Gram-negative bacteria, including common respiratory and skin pathogens.
- BCECF-AM
Catalog No.:BCC5969
CAS No.:117464-70-7
- Triptonodiol
Catalog No.:BCN6782
CAS No.:117456-87-8
- Wilforol E
Catalog No.:BCN8058
CAS No.:117456-86-7
- Xenin 8
Catalog No.:BCC5876
CAS No.:117442-28-1
- 2-Methyl-6-(p-tolyl)heptane-2,3-diol
Catalog No.:BCN7249
CAS No.:117421-22-4
- D-CPP-ene
Catalog No.:BCC6999
CAS No.:117414-74-1
- 4-O-beta-Glucopyranosyl-cis-coumaric acid
Catalog No.:BCN1608
CAS No.:117405-48-8
- AZD2461
Catalog No.:BCC2214
CAS No.:1174043-16-3
- Dimethylwulignan A1
Catalog No.:BCN3624
CAS No.:117404-43-0
- Artoheterophyllin B
Catalog No.:BCN6050
CAS No.:1174017-37-8
- Endothelin 3 (human, rat)
Catalog No.:BCC5713
CAS No.:117399-93-6
- AZD6482
Catalog No.:BCC2523
CAS No.:1173900-33-8
- Prionitin
Catalog No.:BCN4855
CAS No.:117469-56-4
- Sesamoside
Catalog No.:BCN6051
CAS No.:117479-87-5
- ROX NHS ester, pure 6- isomer
Catalog No.:BCC3587
CAS No.:117491-83-5
- Neuromedin U (rat)
Catalog No.:BCC5847
CAS No.:117505-80-3
- Ustusol A
Catalog No.:BCN7719
CAS No.:1175543-02-8
- 2alpha,9alpha,11-Trihydroxy-6-oxodrim-7-ene
Catalog No.:BCN7741
CAS No.:1175543-03-9
- Ustusolate E
Catalog No.:BCN7789
CAS No.:1175543-06-2
- threo-6'-Hydroxyustusolate C
Catalog No.:BCN6930
CAS No.:1175543-07-3
- DMXAA (Vadimezan)
Catalog No.:BCC3644
CAS No.:117570-53-3
- Calpeptin
Catalog No.:BCC2351
CAS No.:117591-20-5
- Coronarin E
Catalog No.:BCN6052
CAS No.:117591-81-8
- 6-Hydroxymethylherniarin
Catalog No.:BCN3573
CAS No.:117597-79-2
Preparation and characterization of cefditoren pivoxil-loaded liposomes for controlled in vitro and in vivo drug release.[Pubmed:26491316]
Int J Nanomedicine. 2015 Oct 1;10 Suppl 1:149-57.
BACKGROUND: The application of antibiotics has been limited due to weak biodistribution and pharmacokinetics. Encapsulation of these drugs in lipid vesicles might be a good solution for obtaining the required properties. Liposomes are one of the most suitable drug-delivery systems to deliver the drug to the target organ and minimize the distribution of the drug to non-target tissues. OBJECTIVE: The study reported here aimed to develop Cefditoren Pivoxil liposomes by thin-film hydration, characterize them in terms of physical interactions, and undertake in vitro and in vivo release studies. METHODOLOGY: The pre-formulation studies were carried out using Fourier-transform infrared spectroscopy and differential scanning calorimetry. Cefditoren Pivoxil liposomal formulations were formulated by thin-film hydration using biomaterials ie, soya lecithin and cholesterol in different molar ratios. The best molar ratio was determined by in vitro studies such as entrapment efficacy, particle size distribution, and diffusion. RESULTS: From the in vitro release studies, it was found that the formulation that contained soya lecithin and cholesterol in a 1.0:0.6 molar ratio gave good entrapment of 72.33% and drug release of 92.5% at 36 hours. Further, the formulation's zeta potential and surface morphology were examined and stability and in vivo studies were undertaken evaluating the pharmacokinetic parameters, which showed promising results. CONCLUSION: Formulation CPL VI showed the maximum drug-loading capacity of 72.3% with good controlled release and acceptable stability when compared with the other formulations. In vivo studies in rabbits showed that the drug release from the liposomes was successfully retarded with good controlled release behavior which can be used to treat many bacterial infections with a minimal dose.
A Comparison of Cefditoren Pivoxil 8-12 mg/kg/day and Cefditoren Pivoxil 16-20 mg/kg/day in Treatment of Children With Acute Presumed Bacterial Rhinosinusitis: A Prospective, Randomized, Investigator-Blinded, Parallel-Group Study.[Pubmed:26045911]
Clin Exp Otorhinolaryngol. 2015 Jun;8(2):129-35.
OBJECTIVES: Cefditoren Pivoxil (CDT) has been used in the treatment of rhinosinusitis. However, little is known about the efficacy of this drug at low and high doses. This study was to compare the efficacy and safety of low dose (8-12 mg/kg/day) and high dose (16-20 mg/kg/day) CDT in the treatment of children with uncomplicated acute rhinosinusitis (ARS). METHODS: This investigation was a randomized, investigator-blinded, and parallel study, conducted in patients (aged 1-15 years) with a clinical diagnosis of uncomplicated ARS. Two groups of patients randomly received low dose or high dose CDT for 14 days. Patients' symptoms were assessed quantitatively using a quantitative symptom score (the S5 score). The changes in sinus symptoms and adverse events were provided by patients and their parents/caregivers. The response rate and adverse effects were evaluated at days 7 and 14. The relapse rate was recorded at days 21 and 28. The recurrences of sinus symptoms at day 60 were also assessed. RESULTS: One hundred forty patients were recruited and randomized; 72 received low dose CDT (group I) and 68 received high dose CDT (group II). There were no significant differences in demographic data including sex, age, presenting symptoms, medical history, and X-ray findings between two groups. The responses rate at day 14 in groups I and II were 95.5% and 95.4%, respectively (P>0.99). There were no significant differences between groups in relapse rate at day 28 and no recurrence at day 60 in either group. The most common treatment-related adverse events were diarrhea (4.2% in group I vs. 2.9% in group II) and vomiting (2.8% in group I vs. 10.3% in group II). There was no statistically significant difference in adverse events between groups. CONCLUSION: Both low and high doses regimens of CDT appeared a similar clinical outcome for treatment in uncomplicated ARS in pediatric patients.
Efficacy and safety of 3 day versus 7 day cefditoren pivoxil regimens for acute uncomplicated cystitis: multicentre, randomized, open-label trial.[Pubmed:27733519]
J Antimicrob Chemother. 2017 Feb;72(2):529-534.
BACKGROUND: Fluoroquinolone-non-susceptible Escherichia coli isolated from patients with acute uncomplicated cystitis are a matter of increasing concern. Cefditoren Pivoxil is an oral, beta-lactamase-stable, extended-spectrum cephalosporin that is effective against fluoroquinolone-non-susceptible bacteria. OBJECTIVES: To evaluate the clinical and microbiological efficacies of Cefditoren Pivoxil against acute uncomplicated cystitis and to determine the optimal duration of Cefditoren Pivoxil treatment. METHODS: We compared 3 and 7 day regimens of Cefditoren Pivoxil in a multicentre, randomized, open-label study. RESULTS: A total of 104 female patients with acute uncomplicated cystitis were enrolled and randomized into 3 day (n = 51) or 7 day (n = 53) treatment groups. At first visit, 94 bacterial strains were isolated from the 104 participants of which 81.7% (85/104) were E. coli. Clinical and microbiological efficacies were evaluated 5-9 days following administration of the final dose of Cefditoren Pivoxil. The clinical efficacies of the 3 and 7 day groups were 90.9% (40/44) and 93.2% (41/44), respectively (P = 1.000). The microbiological efficacies of the 3 and 7 day groups were 82.5% (33/40) and 90.2% (37/41), respectively (P = 0.349). There were no adverse events due to Cefditoren Pivoxil treatment, with the exception of a mild allergic reaction in one patient, after which the Cefditoren Pivoxil was exchanged for another antimicrobial. CONCLUSIONS: Cefditoren Pivoxil is safe and effective for uncomplicated cystitis, with no significant differences in clinical and microbiological efficacies between 3 and 7 day regimens.
